



US 20210405029A1

(19) **United States**(12) **Patent Application Publication**  
**ADZHUBEI et al.**(10) **Pub. No.: US 2021/0405029 A1**(43) **Pub. Date: Dec. 30, 2021**(54) **COMPOUNDS INHIBITING NEF-CALNEXIN  
INTERACTION**(71) Applicant: **THE GEORGE WASHINGTON  
UNIVERSITY, A  
CONGRESSIONALLY  
CHARTERED NOT-FOR-PROFIT,**  
Washington, DC (US)(72) Inventors: **Alexei ADZHUBEI**, Moscow (RU);  
**Michael BUKRINSKY**, Potomac, MD  
(US); **Ruth HUNEGNAW**, Arlington,  
VA (US)(21) Appl. No.: **17/410,882**(22) Filed: **Aug. 24, 2021****Related U.S. Application Data**(62) Division of application No. 16/841,444, filed on Apr.  
6, 2020, now Pat. No. 11,131,661, which is a division  
of application No. 16/069,483, filed on Jul. 11, 2018,  
now Pat. No. 10,684,274, filed as application No.  
PCT/US2017/013236 on Jan. 12, 2017.(60) Provisional application No. 62/277,720, filed on Jan.  
12, 2016.**Publication Classification**(51) **Int. Cl.****G01N 33/50** (2006.01)  
**A61K 31/18** (2006.01)  
**A61K 31/167** (2006.01)  
**A61K 31/404** (2006.01)  
**C07C 223/06** (2006.01)  
**C07C 381/00** (2006.01)  
**C07D 209/56** (2006.01)(52) **U.S. Cl.****CPC** ..... **G01N 33/5041** (2013.01); **A61K 31/18**  
(2013.01); **A61K 31/167** (2013.01); **A61K**  
**31/404** (2013.01); **G01N 33/502** (2013.01);  
**G01N 2500/02** (2013.01); **C07C 381/00**  
(2013.01); **C07D 209/56** (2013.01); **G01N**  
**2333/163** (2013.01); **G01N 2333/4727**  
(2013.01); **C07C 223/06** (2013.01)

(57)

**ABSTRACT**

The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.

**Specification includes a Sequence Listing.**